Document Detail


Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
MedLine Citation:
PMID:  22483337     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of this study was to evaluate the plasma coenzyme Q(10) (CoQ(10)) concentration, a vitamin-like substance found in every cell, which is also viewed as the most effective membrane antioxidant, of thalassemic patients and investigate the effect of chelating agents and ferritin levels on its concentration in patients with β-thalassemia major (β-TM). The study included 44 β-TM patients undergoing deferasirox (DFRA) or deferoxamine (DFO) chelation monotherapies or combined therapy with deferiprone (L1) and DFO, 20 patients with β-thalassemia (β-thal) traits and a control group of 22 healthy sex- and age-matched subjects. Complete blood counts, liver and renal function tests, lipid profiles, ferritin and plasma CoQ(10) [by high performance liquid chromatography (HPLC)] were analyzed. The mean age (14.7 ± 7.3 years; median 14.3 years) and sex (26 males, 18 females) of the β-TM patients were not statistically different from the β-thal trait patients and the control group. The plasma CoQ(10) concentration was 0.425 ± 0.136 μmol/L in β-TM patients, 0.508 ± 0.159 μmol/L in the β-thal trait patients and 0.534 ± 0.133 μmol/L in the control group. The difference was significant in both the β-TM (p < 0.001) and β-thal trait patients (p <0.05) compared to the control group. The CoQ(10) concentration was also associated with ferritin levels in β-TM patients; the β-TM patients with high ferritin levels had a lower CoQ(10) (p <0.05) concentration. Also, higher plasma CoQ(10) levels were detected in β-TM patients undergoing DFRA treatment, according to combined therapy administered (0.457 ± 0.115 vs. 0.382 ± 0.127 mg/dL respectively, p <0.05). In conclusion, both the β-thal trait and β-TM patients have lower antioxidant capacity as demonstrated by the lower CoQ(10) levels. The type of chelating agents and ferritin levels are factors effecting CoQ(10) concentration in β-TM patients.
Authors:
Cigdem Karakukcu; Musa Karakukcu; Ekrem Unal; Turkan Patiroglu; Mehmet A Ozdemir; Yasemin A Torun; Peter H Tang
Related Documents :
19293357 - Pulmonary hypertension in peritoneal dialysis patients: prevalence and risk factors.
19530047 - Primary peritonitis due to brucellosis mimicking tuberculous peritonitis.
16825017 - Interrelationship between uremic toxicity and oxidative stress.
6630457 - Group jk corynebacterium peritonitis in a patient undergoing continuous ambulatory peri...
10332797 - Intraoperative somatosensory evoked potential findings in acute and chronic spinal cana...
19255297 - Nonthyroidal illness syndrome and prolonged mechanical ventilation in patients admitted...
Publication Detail:
Type:  Journal Article     Date:  2012-04-06
Journal Detail:
Title:  Hemoglobin     Volume:  36     ISSN:  1532-432X     ISO Abbreviation:  Hemoglobin     Publication Date:  2012  
Date Detail:
Created Date:  2012-05-08     Completed Date:  2012-10-09     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  7705865     Medline TA:  Hemoglobin     Country:  England    
Other Details:
Languages:  eng     Pagination:  219-29     Citation Subset:  IM    
Affiliation:
Department of Biochmistry, Training and Research Hospital, Ataturk Street, Kayseri, Turkey. ckarakukcu@hotmail.com219
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Benzoates / therapeutic use
Chelation Therapy / methods*
Child
Child, Preschool
Deferoxamine / therapeutic use
Drug Therapy, Combination
Female
Ferritins / blood*
Humans
Iron Chelating Agents / therapeutic use
Male
Pyridones / therapeutic use
Treatment Outcome
Triazoles / therapeutic use
Ubiquinone / analogs & derivatives*,  blood
Young Adult
beta-Thalassemia / blood*,  drug therapy*
Chemical
Reg. No./Substance:
0/Benzoates; 0/Iron Chelating Agents; 0/Pyridones; 0/Triazoles; 1339-63-5/Ubiquinone; 2BTY8KH53L/deferiprone; 303-98-0/coenzyme Q10; 70-51-9/Deferoxamine; 9007-73-2/Ferritins; V8G4MOF2V9/deferasirox

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Roughness assessment and wetting behavior of fluorocarbon surfaces.
Next Document:  Structural analysis of the O-specific polysaccharide from the lipopolysaccharide of Aeromonas veroni...